VIP and Autoimmunity: Over the years, the potent anti-inflammatory effects and immunoregulatory capacity of vasoactive intestinal peptide (VIP), mediated by its receptors VPAC1 and VPAC2, have confirmed the potential of the VIP/VPAC axis in the management of various inflammatory and autoimmune disorders.